Curis Inc.


Stock Update (NASDAQ:CRIS): Curis, Inc. and Aurigene Extend Exclusivity Period Of Immuno-Oncology And Precision Oncology Collaboration

Curis, Inc. (NASDAQ:CRIS) announced that it has exercised its option to extend the exclusivity period with Aurigene under the collaboration, license and option …

Company Update (NASDAQ:CRIS): Curis, Inc. Announces Grant Approval of Inducement Stock Options to Purchase 18,000 Shares

Curis, Inc. (NASDAQ:CRIS) announced that on January 1, 2017, the independent Compensation Committee of the Board of Directors of Curis approved the grant …

Stock Update (NASDAQ:CRIS): Curis, Inc. Appoints Lori A. Kunkel, M.D. to Board of Directors

Curis, Inc. (NASDAQ:CRIS) announced the appointment of Lori A.

Company Update (NASDAQ:CRIS): Curis, Inc. Expands Oncology Pipeline with an Oral Small Molecule PD-L1/TIM-3 Immune Checkpoint Antagonist

Curis, Inc. (NASDAQ:CRIS) announced the expansion of its pipeline with CA-327, an oral, small molecule immune checkpoint antagonist targeting programmed death ligand-1 (PD-L1) and …

Company Update (NASDAQ:CRIS): Aurigene to Invest in Curis, Inc. at Premium Through Waiver of Certain Milestone Payments Under Collaboration Agreement

Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of cancer, today …

Company Update (NASDAQ:CRIS): Curis, Inc. Announces Dosing of First Patient in a Phase 1 Trial of CA-170, the First Oral Small Molecule Drug Candidate to Target and Inhibit Immune Checkpoints

Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced …

Company Update (NASDAQ:CRIS): Curis, Inc. Announces FDA Acceptance of Investigational New Drug Application for CA-170

Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced …

Stock Update (NASDAQ:CRIS): Curis, Inc. Reports First Quarter 2016 Financial Results

Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human …

Stock Update (NASDAQ:CRIS): Curis, Inc. Announces Publication of CUDC-907 Phase 1 Clinical Trial Data in Lancet Oncology

Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective drug candidates for the treatment of human cancers, …

Company Update (NASDAQ:CRIS): Curis, Inc. Reports Fourth Quarter and Year-End 2015 Financial Results

Curis, Inc. (NASDAQ:CRIS), a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, today reported …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts